The ORR in MYC-altered DLBCL patients was 64% (7/11), with 71% (5/7) in CUDC-907 monotherapy and 50% (2/4) in the combination of CUDC-907 and rituximab [217]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.